Call Now Open

2025 Oxford-Harrington Rare Disease Scholar Award

You've just added:

Scholars

Maximilian Konig, MD

Maximilian Konig, MD

Johns Hopkins University

Disease Areas

Hematology, Immunology, Musculoskeletal, Reproductive


Focus

Autoantigen-Specific T Cell Therapies for the Prevention and Treatment of Antiphospholipid Syndrome


Scholar Profile

2023 Harrington Scholar-Innovator

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder that causes blood clots and pregnancy complications, including repeated miscarriages. Existing treatments—commonly lifelong therapy with blood thinners—do not address the underlying autoimmune problem and often fail. Rheumatologist, Maximilian Konig, MD, and his team have developed a way to reprogram the immune system to stop the autoimmune attack without suppressing its vital functioning.

The groundbreaking approach, called CATCR (chimeric autoantigen T-cell receptor, pronounced “catcher”), involves immune cell engineering similar to CAR-T cell technology— except that the scientists genetically edit the T-cell receptor directly, turning them into precise weapons against rogue B cells that drive APS.

“In patients suffering from APS, a small subset of B cells becomes self-reactive—they recognize and attack an abundant plasma protein called beta-2-glycoprotein I (B2GPI),” explains Dr. Konig. “These rogue B cells also make the autoantibodies that cause blood clots and pregnancy loss in APS. Armored with CATCRs, we have shown that a very small number of re-engineered T-cells can eliminate the B2GPI-reactive B cells while sparing all normal B cells to fight infection.”

With Harrington support, Dr. Konig is refining structural characteristics and functions of CATCR-T cells while conducting efficacy and safety studies in humanized models.

“Having a team of experts in drug manufacturing, regulatory affairs, and commercial development is a major advantage in advancing CATCR,” Dr. Konig says. “We hope to leverage this technology to treat patients with APS first, and eventually design precision cellular therapies for various other autoimmune and rheumatic diseases.”

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.